肿瘤新生血管及分子靶向治疗新策略

肿瘤血管靶向治疗是基于肿瘤新生血管与正常血管的不同，药物专一识别并阻断肿瘤新生血管，使肿瘤细胞“饿死”，而不影响正常细胞。从1971年Folkman提出“饿死肿瘤”的假说到2004年第一个血管靶向药物上市，记载着30多年领域发展的传奇经历。当今，肿瘤血管已成为生物医学和临床研究的热点，新的发现层出不穷。该文重点介绍肿瘤血管新靶点、新机制、新药物与未来发展。

Angiogenesis:A Promising Strategy for Tumor Therapy

Inhibiting angiogenesis is a promising strategy for treatment of cancer, whoes aim is to block tumor blood vessels and allow tumor die from starvation. In 1971 Folkman hypothesed that tumor growth is angiogenesis-dependent. In 2004 the first antiangiogenesis drug received approval from the US FDA for cancer treatment. Angiogenesis is now a hot area of tumor biology. Various novel targets, mechanism and inhibitors have been found. This review will focus on recent progress of these projects providing insight into angiogenesis research.